Clinical Trial Update: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating pegfilgrastim given on day 3 after chemotherapy to reduce neutropenia in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)

Snippet

Sponsor: Eunseong Medical Foundation Good GANG-AN HOSPITAL | Conditions: Breast Neoplasms | Phase 4 | Status: UNKNOWN